DeepMed Research

Tegafur,Gimeracil and Oteracil Potassium

Generic Name: Tegafur,Gimeracil and Oteracil Potassium

Indication: 用于不能切除的局部晚期或转移性胃癌。

用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。

Clinical Trials

Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer

Phase 2

Recruiting

Conditions: Stomach Neoplasms
Gastric Cancer
Linitis Plastica of Stomach

Interventions: Drug: Tislelizumab
Drug: Oxaliplatin
Drug: S-1
Drug: Capecitabine

First Posted Date: 2024-06-11

Last Posted Date: 2024-06-11

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 53

Registration Number: NCT06451211

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Gastric Cancer
Gastro Esophageal Junction Cancer

Interventions: Drug: Surufatinib
Drug: Sintilimab
Drug: Oxaliplatin
Drug: S1

First Posted Date: 2024-06-07

Last Posted Date: 2024-06-07

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06447636

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

Phase 2

Recruiting

Conditions: Fruquintinib
Raltitrexed
S-1

Interventions: Drug: Fruquintinib
Drug: S-1
Drug: raltitrexed

First Posted Date: 2024-05-23

Last Posted Date: 2025-01-22

Lead Sponsor: Meng Qiu

Target Recruit Count: 66

Registration Number: NCT06427005

Locations: 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: RC48
Drug: Adebrelimab
Drug: Apatinib
Drug: S-1

First Posted Date: 2024-04-26

Last Posted Date: 2024-05-13

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 32

Registration Number: NCT06385873

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

Phase 2

Recruiting

Conditions: Gastric Cancer
Gastric Cancer Metastatic to Regional Lymph Nodes

Interventions: Drug: Sintilimab
Radiation: Extraperitoneal radiation therapy
Drug: Oxaliplatin
Drug: S-1

First Posted Date: 2024-04-02

Last Posted Date: 2024-04-02

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 40

Registration Number: NCT06341595

Locations: 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Phase 2

Active, not recruiting

Conditions: Gastric Cancer

Interventions: Drug: ONO-4578
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Nivolumab
Drug: S-1
Drug: Placebo

First Posted Date: 2024-02-13

Last Posted Date: 2024-07-29

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 210

Registration Number: NCT06256328

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of

and more 60 locations

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Tislelizumab
Drug: S-1 therapy
Drug: low dose SOX therapy

First Posted Date: 2024-02-02

Last Posted Date: 2024-02-02

Lead Sponsor: First Affiliated Hospital of Wenzhou Medical University

Target Recruit Count: 40

Registration Number: NCT06238167

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Phase 3

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: KC1036
Drug: Irinotecan
Drug: Docetaxel
Drug: S-1

First Posted Date: 2024-01-08

Last Posted Date: 2024-03-07

Lead Sponsor: Beijing Konruns Pharmaceutical Co., Ltd.

Target Recruit Count: 490

Registration Number: NCT06194734

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)

Phase 2

Recruiting

Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma

Interventions: Drug: S-1
Drug: Toripalimab
Radiation: Intensity-modulated radiotherapy

First Posted Date: 2024-01-02

Last Posted Date: 2024-03-12

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 140

Registration Number: NCT06187597

Locations: 🇨🇳
Mian Xi, Guangzhou, Guangdong, China

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Previously AG Chemotherapy Treated Pancreatic Cancer

Interventions: Drug: Zimberelimab
Drug: Oxaliplatin
Drug: S-1
Drug: Irinotecan

First Posted Date: 2023-12-12

Last Posted Date: 2023-12-12

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 19

Registration Number: NCT06166589

Locations: 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy